Drugs / Vindesin
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 3 | NCT02042690 Comparator | Jul 2014 → Feb 2018 | acute lymphoblastic leukemia | Peking University | Completed | No outcome recorded |
| Phase 3 | NCT01659099 Background | Sep 2012 → Aug 2016 | diffuse large B-cell lymphoma | The Lymphoma Academic Research Organisation | Terminated | Missed primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Vindesin | “Drug:Vindesin 4mg/d，d4，d11, IV,in cycle 2,4,6” NCT02042690 ↗ |
| Route | Intravenous | “Vindesin 4mg/d，d4，d11, IV” NCT02042690 ↗ |